



Schizophrenia Research and Care—Where Science Meets the Mind's Mysteries

Ratnadeep Chowdhury¹, Somdutta Bhattacharyya¹, Shounak Sarkhel², Debjani Sarkar², Saptarshi Paul², Simanta Bhattacharjee¹

¹Sister Nivedita University, Action Area I, Newtown, New Town, Chakpachuria, Kolkata- 700156, WB

²JIS university, 81, Nilgunj Rd, Jagarata Pally, Deshpriya Nagar, Agarpara, Kolkata -700109, WB.

(Received: 14 May 2024

Revised: 01 June 2024

Accepted: 13 July 2024)

KEYWORDS

cognitive impairment, negative symptoms, treatment-resistant Schizophrenia, non-dopaminergic antipsychotics, premature mortality, cognitive remediation, virtual reality.

ABSTRACT:

Introduction: Schizophrenia is an ailment of mental capabilities which ends up in the affected person deciphering their environment in a manner exclusive from the conventional reality. The term “Schizophrenia” emerged throughout the early 1900s to symbolize a cluster of various syndromes which significantly affected the social, practical and organic exceptional of lifestyles.

Objectives: At a fundamental level, Schizophrenia can be conceptualized as a pathological condition or more precisely, a cognitive disorder that engenders an altered perception of one's environment, deviating from the norms of conventional reality.

Methods: For numerous decades, individuals with schizophrenia have been labeled as "Schizophrenics". A term that has contributed to a setback in the identification and management of the disorder for a considerable duration^{3,4}. Since the beginning of the 21st century, there has been a notable increase in focus on the examination, investigation and prediction of the diverse aspects pertaining to our mental well-being.

Results: The treatment of Schizophrenia has superior in latest years by means of leaps and limits with the improvement of new age simulation strategies such as digital truth in addition to new age 2d-generation non-dopaminergic antipsychotics, which is more flexible and customizable treatment alternatives. Treatment options have been advanced with the aid of the virtual reality to provide cognitive remediation within the sufferers of Schizophrenia.

Conclusions: Though the remedies do not reach the ultimate goal and effectiveness to control of the numerous illnesses through the sufferers of Schizophrenia but give a higher pleasant life for them and additionally helped in removal of decade lengthy of stigma regarding the ailment consequently encouraging humans to searching for assist. For this reason, encouraging higher techniques for prognosis using biomarkers mainly for the poor symptoms and cognitive impairments. Consequently, the importance of customizable treatment plan is simple to ensure a better future for the patients of the disorder.

1. Introduction

The term "schizophrenia" was first introduced by the esteemed Swiss psychiatrist Paul Eugen Bleuler in a lecture delivered in Berlin on the 24th of April 1908. Since its inception, this terminology has been employed to denote an amalgamation of diverse symptoms, anomalies and ailments that have exerted a deleterious impact on the individual's functional, social, and biological well-being. At a fundamental level, Schizophrenia can be conceptualized as a pathological condition or more precisely, a cognitive disorder that engenders an altered perception of one's environment, deviating from the norms of conventional reality. The manifestation of a typical responses to rudimentary intuitions can give rise to a range of indications including but not limited to delusional ideation, cognitive disarray, inarticulate verbal

expression, impaired cognitive processes and in severe instances- the emergence of paranoid tendencies, perceptual distortions or hallucinations and psychosis^{1,2}. The manifestation of these symptoms frequently gives rise to a state of heightened anxiety, anger and an unwarranted sense of superiority within the afflicted individual. A cognitive orientation that is delay disapproved of within the confines of our established societal framework characterized by human civilization^{7,8}. The societal response to this condition has resulted in the stigmatization of both the illness itself and those afflicted by it. For numerous decades, individuals with schizophrenia have been labeled as "Schizophrenics". A term that has contributed to a setback in the identification and management of the disorder for a considerable duration^{3,4}. Since the beginning of the 21st century, there



has been a notable increase in focus on the examination, investigation and prediction of the diverse aspects pertaining to our mental well-being. Some of the most commonly observed positive symptoms for Schizophrenia can be listed as follows:-

Hallucinations: Hallucinations can be elucidated as a perceptual phenomenon characterized by the erroneous perception of diverse auditory, visual, tactile, olfactory or gustatory stimuli, despite their absence in the immediate vicinity of the individual experiencing them.

Delusions: Delusions may be understood as the contemplation and obstinate belief in a specific factor(s) despite the existence of evident, concrete, and evidence that is against the concerned view.

Disruption and dysfunction of the normal cognitive process in the affected individual is what is referred to as mind disorders. The term "negative symptoms" refers to a variety of characteristics, behaviours, and activities that are often shown by healthy members of our human civilization but are lacking in patients, who are suffering from the condition^{9,10}. The following is a list of some of the unfavourable symptoms of schizophrenia those are most frequently noted by medical professionals¹¹.

Avolition: The phenomenon of lacking motivation and exhibiting a propensity to deviate from established schedules or toil persistently towards a specific objective. This symptom may also be observed as a pervasive apathy and diminished drive, resulting in a compromised quality of life for the individual. The investigation of cognitive function impairment has emerged as a prominent area of interest in contemporary research on Schizophrenia. Cognitive functions encompass a diverse array of mental processes and pathways that facilitate the execution of a wide range of daily activities by individuals^{6,7}. In contemporary times, there has been a notable surge in research endeavours focused on the early detection of Schizophrenia. This emphasis primarily revolves around the identification and evaluation of negative symptoms and cognitive dysfunctions^{12,13}. The ongoing progress in the field of remediation holds great potential for enhancing the rehabilitation and treatment options available to individuals afflicted with this disorder in the coming years.

Psychosis: Psychosis, a multifaceted psychiatric phenomenon, is a condition characterized by a profound disruption in an individual's perception of reality. It

encompasses a range of symptoms, including hallucinations, delusions, disorganized thinking and impaired cognitive functioning.

Difficulties in assessing unpleasant symptoms and recent developments.

Since the first record of the condition was made by Morel in the 1850s, negative symptoms have been a primary focus of research and a difficult therapeutic challenge in the treatment of schizophrenia. This has been the case of right from the beginning of the disorder's documentation. The negative symptoms of the condition are representation of the many impairments and losses that the patient experiences on normal mental functions. It is one of the most frightening and difficult aspects of the schizophrenia condition and it is one of the greatest challenges that doctors encounter when treating and rehabilitating patients^{12,13}. The lack of information regarding the structures of these unpleasant symptoms and the impact they have on the quality of life for those, who are affected by the condition, is one of the most visible gaps in the system. The fact that the negative symptoms of the disease tend to be present with at least a similar intensity throughout the range of schizophrenia episodes poses a challenge¹⁵. This is because, in some situations, the positive symptoms of the disorder tend to ebb and flow based on the efficacy of the therapy that is being received, while in other cases, the positive symptoms of the condition tend to be constant. They have a tendency to worsen with age and the advancement of the condition, which is one of the most upsetting features for the family members and carers of individuals who have schizophrenia^{4,5}. In recent years, the examination of a wide range of unfavourable symptoms has been carried out by carrying out clinical investigations in a variety of assessment scales, with each scale being based on a distinct aspect of the symptoms that are being evaluated. They assist us in determining the various facets of adverse symptoms as well as the intensities of those symptoms when applied to a real-world clinical scenario^{6,7}. This statistical method assists us in designing precise treatment regimens and even the assessment of the efficacies of newly produced anti-psychotic drugs. All of which contribute to ensuring a higher quality of life for the patients. A few of these scales have been touched on in passing throughout this article.

The positive and negative syndrome scale or PANSS, consists of the following items: It is a 30-items scale those



were developed so as to examine the relationship between the positive and negative symptoms that people with schizophrenia²¹ experienced along with determining a compound's level of effectiveness. The scales also assist in developing a predictive validity for the substance in question²².

The Clinical Assessment Interview for Negative Symptoms or CAINS consists of the following questions: The results that are provided by this scale of evaluation are principally based on two different functional subscales. The Motivation and Pleasure (MAP) subscales is an assessment tool that determines the amount of motivation, pleasure, and anticipation in relation to a variety of activities, whether they are vocational or recreational in nature^{28,29}. On the other side, the expressional (EXP) subscale assesses the patient's inability to verbally or physically communicate their sentiments. This might include both vocal and gesture communication. The higher the rating is on this scale, the greater the degree of impairment that is reflected on the patient in question^{30,31}.

The Functioning Assessment Short Test or FAST consists of the following:

The purpose of this examination is to determine the extent to which the patient exhibits difficulty in performing six distinct functional tasks in the society^{32,33,34,35,36}.

These six areas are as follows:

A life led independently and in accordance with one's own conscience.

Being able to carry out occupational duties in an acceptable manner.

Demonstrating a consistent level of cognitive functioning.

Taking responsibility for one's own financial situation.

Keeping up with relationships, whether they are professional or personal.

Methods for occupying oneself and making productive use of spare time.³⁸

The Quality-of-life scale, sometimes known as the QLS:

The quality of life of schizophrenic patients is specifically evaluated using this scale, which was established for that purpose. Based on the four basic components that are impacted by the symptoms^{39,40,41}, the scale assigns

grades on an increasing gradient that ranges from dysfunction to normality. The first is the utilization of shared resources and facilities, which includes 42.

The preservation of one's personal relationships.

The ability to function on an intra-psyche and personal level.

The responsibility of contributing to the establishment of stable financial circumstances.

Clinical researchers have found by using these scales—they are better able to collect extensive statistical data and carry out a variety of clinical studies in order to develop a more effective treatment and rehabilitation strategy for patients whose conditions are varied in both severity and urgency. Social and non-social abnormalities in schizophrenia-related cognitive impairment. The numerous mental operations, those are essential for living a normal existence, are together referred to as the cognitive functions of the human body. One of the most prominent negative consequences that schizophrenia has on a person's mental faculties is a disruption of the aforementioned cognitive processes.

Memory, logical reasoning and the ability to solve problems are just few of the cognitive functions those are essential to our continued existence as a social species^{36,18}. The phrase "cognitive functions" incorporates all of these different psychological abilities. Damage and alterations in the hippocampus and medial temporal lobes have been found in studies to be directly connected with changes in the cognitive processes^{11,19}.

Schizophrenia patients have a significantly lower quality of life than the general population due to the impairments those are caused by their conditions²³. Because these patients lack the day-to-day aptitude and problem-solving skills, their lives are filled with a wide array of obstacles.

The following discussion can be had on these social and non-social aspects of cognitive impairment^{20,21}. The followings are some explanations those can be given for certain social cognitive deficiencies which have been reported in patients with schizophrenia:

The inability to recognize human emotions in the case of other people and the inability of the patient to manage their own emotions. The difficulty in adhering to particular social norms of our civilized culture and in interpreting nonverbal the inability to carry an interaction in a civilized balanced manner due to the aforementioned



handicap of understanding the thoughts, beliefs and verbal cues of the person the patient is communicating with. This is related to the patient's incapacity to comprehend the thoughts, beliefs and verbal cues of the other person.

In patients with schizophrenia, it is also typical to find some cognitive deficiencies those are not related to social interaction. These deficits might be explained as follows:

A slower speed of mental thinking that results in an inability to carry out simple logical activities, arithmetic operations and other fundamental goal-focused works.

A significant disadvantage in terms of the capacity to store memories and to keep vital information from visual, auditory and other sources in working memory for an extended length of time.

Keeping one's attention focused on a certain goal over the course of an extended amount of time, while carrying out a task that lasts longer than a few minutes. Because of these social and non-social deficiencies, a person with schizophrenia might become socially handicapped over time as the intensity of their symptoms increases. The impairment of these cognitive abilities can be labelled as one of the key causes of stigmatization of schizophrenia patients over the centuries^{15,16}. This stigmatization has been a problem for individuals with schizophrenia for a long time. As a result, one of the primary focuses of research on schizophrenia is the restoration of cognitive function in patients who have suffered from its symptoms. If research in this area gets success, it will not only help in the treatment and rehabilitation of patients, but it will also go a long way towards reducing the stigma that has been attached to the condition for centuries, which will encourage more people to seek help and therapy^{24,25}.

Cognitive rehabilitation in schizophrenia: In new horizons the implementation of cognitive remediation interventions in individuals diagnosis with Schizophrenia represents a pivotal and indispensable endeavour aimed at enhancing their overall quality of life^{3,5}. In contemporary times, the field of cognitive remediation has witnessed the emergence of two innovative methodologies, which will be elucidated as follows:- (15,16,17).




Fig:1-Coronal Section of Brain




Fig:2-Ventricular System of Brain

2. Objectives

The field of research pertaining to the diagnosis, differentiation and treatment of Schizophrenia has experienced significant advancements in tandem with the ongoing trend. The initial and paramount advancement in this domain entailed the evolutionary trajectory of diagnosing Schizophrenia, commencing from its nascent phases and the subsequent categorization of diverse manifestations displayed by afflicted individuals into positive symptoms and negative symptoms^{5,6}. The positive symptoms encompass a range of behaviours exhibited by individuals afflicted with the disease, which are not typically observed within the broader human population^{2,4}.

3. Methods

The Cognitive Remediation Approach of Making Up for Losses:

The compensatory approach method represents the conventional paradigm for cognitive remediation in individuals diagnosed with Schizophrenia. The therapeutic interventions utilized within this framework aim to ameliorate the cognitive impairments observed in



individuals by harnessing the assistance of environmental elements and fostering the acquisition of novel skills. This methodology encompasses a range of activities, including traditional pen-to-paper exercises, computer-based tasks as well as outdoor activities that involve moderate physical exertion^{26,27}. The activities are designed in a manner that specifically targets the fundamental aspects of cognition including memory, logical reasoning and focused attention. These activities are frequently conducted under the guidance of skilled therapeutic professionals and contribute to patients' long-term enhancement of their quality of life.^{28,29}.

The Cognitive Enhancement Therapeutical Approach (CETA) is a novel framework that aims to optimize cognitive functioning through targeted interventions. This approach draws upon the principles of cognitive psychology and neuroscience to develop evidence-based strategies for enhancing cognitive abilities. CETA is grounded in the understanding that Cognitive Enhancement therapy (CET) is a therapeutic approach that relies on harnessing the neuroplasticity exhibited by the human nervous system. This therapeutic intervention aims to harness the phenomenon of neuroplasticity exhibited by the remaining neural networks with the goal of promoting a discernible amelioration in the cognitive deficits observed in specific regions. The ultimate objective is to facilitate a partial reinstatement of normal cognitive functioning, thereby enhancing the overall quality of life for the individual on undergoing treatment^{30,31}. The therapeutic regime is structured as a biweekly intervention, accompanied by ongoing patient monitoring. The proposed intervention employs a dual strategy to optimize cognitive abilities, specifically memory functions, attention spans and logical reasoning, while concurrently mitigating undesirable aspects such as emotional instability and distractions that may impede performance on target or reward-based tasks. There exists ample empirical evidence supporting the efficacy of both of these therapeutic approaches in facilitating substantial positive outcomes in the rehabilitation of individuals diagnosed with Schizophrenia. Consequently, it is plausible to employ these approaches in conjunction, thereby establishing an integrated treatment modality. This combined method can be implemented until the emergence of more innovative interventions that aim to expedite and enhance the remediation process for this particular disorder^{32,33}.

Approaches to Cognitive Enhancement Therapy:

Cognitive Enhancement therapy (CET) is a therapeutic approach that capitalizes on the utilization of neuroplasticity, a phenomenon exhibited by the human nervous system. This multi-structured approach aims to enhance cognitive functioning through targeted interventions. The objective of this therapeutic intervention is to harness the phenomenon of neuroplasticity exhibited by the remaining neural networks with the aim of facilitating an amelioration in the areas of cognitive impairment. The ultimate goal is to reinstate a certain level of normal functioning in the patient's life³⁷. The therapeutic intervention is structured to occur biweekly with a concurrent and ongoing monitoring of the patient. The proposed intervention employs a dual strategy aimed at augmenting cognitive processes related to memory, attention and logical reasoning in individuals, while concurrently mitigating undesirable aspects such as emotional volatility and distractions that may impede performance on tasks contingent upon specific objectives or incentives. There exists ample empirical evidence supporting the efficacy of both of these approaches in facilitating substantial positive outcomes in the rehabilitation of individuals diagnosed with Schizophrenia. Consequently, it is plausible to employ these approaches in conjunction, thereby establishing an integrated treatment modality, until more innovative interventions emerge that aim to expedite and enhance the remediation process for this particular disorder^{34,35,36}.

Cognitive impairment and depressive symptoms biomarkers:

Biomarkers refer to compounds or molecules that upon detection in bodily fluids, serve as indicators for the presence of a specific disease or disorder within the patient's physiological system. Given the complex nature of Schizophrenia, a multifaceted disorder characterized by a diverse range of symptoms and distressing experiences, the identification of a singular biomarker capable of definitively detecting the presence of this psychiatric condition within an individual's physiological system remains elusive⁴⁴. In a captivating endeavour, researchers are currently exploring the potential of biomarkers, specifically in relation to the emergence of the most formidable facets of Schizophrenia therapy, namely negative symptoms and cognitive impairment. The present discourse will elucidate a subset of biomarkers that are presently under investigation for their potential



association with specific negative symptoms and cognitive impairments.

Neurotropic factors originate in the brain:

The concept that the brain came up with proteins known as neurotropic factors are crucial components in the expansion and maturation of neurons as well as the control of neurotransmitters at synaptic junctions and the promotion of the formation of new synapses. Recent clinical researches have commented on a probable association of some negative symptoms of schizophrenia with a reduced level of these components in the blood plasma/serum⁴³. It has been discovered that certain cognitive activities, such as tasks involving semantic formation, are impaired when there is a reduction in the amount of brain-derived neurotropic factors found in the blood.

Patients with schizophrenia are evaluated using a variety of monoamine neurotransmitters as potential biomarkers. There are three key neurotransmitters which have been believed to be effective as biomarkers while monitoring patients with schizophrenia. These neurotransmitters include dopamine, norepinephrine and serotonin. Dopamine receptors DRD 2, DRD 3, and DRD 4 were the focus of a significant portion of the research that was carried out. A binding and expression of mRNA was shown to be particularly larger for the receptor DRD 2 in the lymphocytes of patients affected by schizophrenic disease⁴⁵ as demonstrated by our investigation. In the case of DRD 3, the expression of mRNA was also discovered to be higher in the lymphocytes. However, it is interesting to note that this distinctive increase was observed in patients who suffered from schizophrenia as well as individuals who were unable to accept the anti-psychotic medications that were provided to them¹⁹. In contrast, the mRNA for DRD 4 receptors was shown to be less expressed or to be unchanged in the cases of patients with schizophrenia. Recognition, investigation, and analyses of these biomarkers all contribute to the early phases of pathogenesis for schizophrenia disease, which allows for earlier recognition of the condition. This would result in the management of negative symptoms and cognitive impairments in the early phases, so ensuring therapy before the aggregation, which in turn would result in a more complete recovery^{13,46}.

Virtual reality in the assessment and care of people with Schizophrenia:

In the contemporary era characterized by advanced technological advancements, virtual reality stands as a remarkable feat of human civilization. The artificial virtual reality (VR) system employs a combination of visual, auditory and three-dimensional (3D) stimuli to fabricate a targeted scenario. This is achieved through the utilization of purpose-built headsets and controllers, which are specifically designed to facilitate the immersive experience. A noteworthy phenomenon worthy of examination is the propensity of individuals afflicted with Schizophrenia, particularly during the advanced stages of the disorder, to inhabit a subjective realm akin to a virtual reality. This state is perpetuated by the individual's own delusions and hallucinations^{18,47}. The therapeutic approach utilizing virtual reality entails the creation of a simulated environment with the aim of alleviating anxiety induced by hallucinations in patients. This intervention fosters a state of tranquillity and security, thereby mitigating heightened palpitations and promoting stabilization of vital physiological parameters, such as blood pressure and heart rate²³. Through extensive research and rigorous clinical studies, a multitude of major approaches have been meticulously developed, warranting a concise discussion as outlined below⁴⁸.

Virtual-reality-based instruction: It is possible to employ virtual reality to do simulations of various real-world circumstances, during which one may observe the patient's response and evaluate the patient's likelihood of surviving in the real world.

Using Virtual Reality to Teach People How to Get Along: It is possible to employ virtual reality in conjunction with traditional treatments in order to expedite the growth of specific social skills that would contribute to an improvement in the patient's quality of life. This would be an advantage for both types of treatment. This method may be utilized to develop aspects of a person's life those are influenced by unpleasant symptoms and cognitive impairment, such as speech, memory, and engagement with other people²³.

Virtual-reality-based avatar treatment.: In the setting of advanced stages of schizophrenia, when patients have already shown hallucinatory experiences and are in the early stages of psychosis, the present study makes use of a unique technique. This approach was applied in the context of patients who had previously been diagnosed with schizophrenia. In the context of therapeutic therapies, the technology of virtual reality (VR) is used by clinicians



to mimic and simulate the perceptual features of hallucinatory experiences that patients have described having. The goal of the therapy is to direct the course of the patient's hallucinations toward a calmer and more secure state by placing the patient in a virtual environment. This helps the patient feel more at ease and improves their mental health overall.²²

VR-Based Cognitive Behaviour Therapy: The process of cognitive behaviour modification can be effectively facilitated in patients through the utilization of Virtual Reality (VR) technology, which provides an immersive and interactive experience. This method involves the gradual and systematic application of positive reinforcement techniques to promote desirable cognitive patterns in individuals. Various activities necessitating mild cognitive responses can be employed to elicit cognitive revitalization in the individual within a closely observed and regulated setting.

Sensitization Reduction through Virtual Reality: In this method, the first step is to establish a setting that is secure and under control. The next step is to subject the patient to a stimulus that has a documented history of bringing on episodes of paranoia. This eventually leads to the patient becoming desensitized to the component that triggered the reaction, which might be some visual, olfactory or aural input. If a certain pattern and recurring hallucinations are noticed in a patient's situation, further use for this tactic may be necessary. Therefore, it is possible to state unequivocally that in the not-too-distant future, virtual reality will play a quite a significant part in the treatment, monitoring and rehabilitation of schizophrenia patients²⁵.

4. Results

Physical health in people with Schizophrenia and antipsychotic treatment: Throughout the annals of history, antipsychotic medications have served as a cornerstone in the therapeutic arsenal for individuals presenting with manifestations of psychosis. The primary objective of antipsychotic interventions is to effectively address the management of positive symptoms in individuals diagnosed with Schizophrenia²⁴. Historically, first-generation antipsychotics have been employed due to their apparent efficacy in mitigating episodes of psychosis and paranoia, which are the predominant positive symptoms manifested by individuals diagnosed with Schizophrenia. Nevertheless, a notable drawback associated with the utilization of first-generation antipsychotics resides in their propensity to induce extrapyramidal symptoms. The

presence of extrapyramidal symptoms exacerbates the challenges associated with reintegrating the patient into society during the rehabilitation process. The historical stigmatization surrounding Schizophrenia and its afflicted individuals can, in part, be ascribed to the manifestation of extrapyramidal symptoms. This can be attributed to the fact that during the initial stages of treatment for Schizophrenia, only available options were the first-generation antipsychotics, which primarily targeted the positive symptoms of the disorder²⁸. Among the frequently observed extrapyramidal symptoms (EPS) are:

-
- Acute dystonia.
- Drug-induced Parkinson's Syndrome.
- Tardive dyskinesia.

The development of antipsychotic medications of the second generation has been of great assistance in the elimination of these extra-pyramidal symptoms¹¹. As a result, this paves the way for a therapy for the schizophrenia disorder that is better, more accurate and more broadly applicable.

Better tolerance and efficacy in new dopaminergic and non-dopaminergic antipsychotics:

The typical antipsychotics used for the treatment in case of Schizophrenia can be classified into two subcategories:

-

First generation or typical antipsychotics: The first generation of antipsychotic medications are usually drugs that act as antagonists for the dopamine receptors. It has also been discovered that these antipsychotics have an effect on inhibiting the activity of noradrenergic, cholinergic and histaminergic receptors. Orally and intravenously are the two most common routes of administration for these. The extra-pyramidal symptoms that can occur alongside the administration of dopaminergic antipsychotics are the primary source of concern associated with their usage. These are the sole kinds of treatment which are utilized to keep the positive symptoms of schizophrenia under control. The presence of extra-pyramidal symptoms, on the other hand, makes patient rehabilitation a challenging endeavour^{48,49}.

Second generation or atypical antipsychotics: Antipsychotic medications belonging to the second-generation act as antagonists for both the D2 dopamine receptor and the receptors for serotonin. The fact is that



non-dopaminergic antipsychotics do not cause patients to experience any extrapyramidal side effects which is the most significant benefit that second-generation antipsychotics have in comparison to the first-generation antipsychotics. Second-generation antipsychotics are more effective in preventing relapses than the first-generation counterparts because they treat both the positive and negative symptoms of schizophrenia⁵⁰.

5. Discussion

One perspective may be stated unequivocally now that so many new studies and investigations have been conducted about schizophrenia. Schizophrenia is a mental illness that may be treated in a variety of ways, including psychotherapy, antipsychotic medication, and even virtual reality. Because there are so many treatment choices available, the route to recovery from schizophrenia may appear confusing and muddled on paper. In every single actual clinical instance, the treatment plan should be individualized for the patient by taking into account the patient's psychological evaluation, the symptoms that are now being shown, the patient's current state of health and other fundamental aspects. It is impossible to overstate the significance of individualized treatment strategies when dealing with a complex disease like schizophrenia, which manifests its symptoms in a myriad of different ways. Even in the case of antipsychotics, a judgment cannot be reached by universal consensus for all of the instances throughout the world. If the positive symptoms become too extreme, it may be necessary to begin treatment with first-generation antipsychotics. This may be the case in certain situations. In a nutshell, the earliest we can deliver a tailored therapy that focuses on the symptoms and condition of each and every patient suffering from schizophrenia around the globe. The sooner we can work toward a better society in which people diagnosed with this condition may lead lives which are full, satisfying and free from the stigma of being labelled as "schizophrenic," the better.

References

- [1] 1. Orsolini L, Pompili S, Volpe U. Schizophrenia: a narrative review of etiopathogenetic, diagnostic and treatment aspects. *Journal of Clinical Medicine*. 2022 Aug 27;11(17):5040.
- [2] 2. Green MF, Lee J, Wynn JK. Experimental approaches to social disconnection in the general community: can we learn from schizophrenia research?. *World Psychiatry*. 2020 Jun;19(2):177.
- [3] 3. Tortorella A. We should improve personalization of management in patients with a diagnosis of schizophrenia. *Journal of clinical medicine*. 2021 Dec 30;11(1):184.
- [4] 4. Mamakou V, Thanopoulou A, Gonidakis F, Tentolouris N, Kontaxakis V. and type 2 diabetes mellitus. *ΕΛΛΗΝΙΚΗ ΨΥΧΙΑΤΡΙΚΗ ΕΤΑΙΡΕΙΑ*. 2018 Jan;29(1):64-73.
- [5] 5. Palmier-Claus J, Griffiths R, Murphy E, Parker S, Longden E, Bowe S, Steele A, French P, Morrison A, Tai S. Cognitive behavioural therapy for thought disorder in psychosis. *Psychosis*. 2017 Oct 2;9(4):347-57.
- [6] 6. Strauss GP, Esfahlani FZ, Galderisi S, Mucci A, Rossi A, Bucci P, Rocca P, Maj M, Kirkpatrick B, Ruiz I, Sayama H. Network analysis reveals the latent structure of negative symptoms in schizophrenia. *Schizophrenia bulletin*. 2019 Sep 11;45(5):1033-41.
- [7] 7. Dawidowski B, Grelecki G, Biłgorajski A, Podwalski P, Misiak B, Samochowiec J. Effect of antipsychotic treatment on neutrophil-to-lymphocyte ratio during hospitalization for acute psychosis in the course of schizophrenia—a cross-sectional retrospective study. *Journal of Clinical Medicine*. 2021 Dec 31;11(1):232.
- [8] 8. Ince Guliyev E, Guloksuz S, Ucok A. Impaired effort allocation in patients with recent-onset schizophrenia and its relevance to negative symptoms assessments and persistent negative symptoms. *Journal of Clinical Medicine*. 2022 Aug 28;11(17):5060.
- [9] 9. González-Rodríguez A, Seeman MV, Díaz-Pons A, Ayesa-Arriola R, Natividad M, Calvo E, Monreal JA. Do sex/gender and menopause influence the psychopathology and comorbidity observed in delusional disorders?. *Journal of clinical medicine*. 2022 Aug 4;11(15):4550.
- [10] 10. Romero-Ferreiro V, García-Fernández L, Aparicio AI, Martínez-Gras I, Dompablo M, Sánchez-Pastor L, Rentero D, Alvarez-Mon MÁ, Espejo-Saavedra JM, Lahera G, Marí-Beffa P. Emotional Processing Profile in Patients with First Episode Schizophrenia: The Influence of Neurocognition. *Journal of Clinical Medicine*. 2022 Apr 6;11(7):2044.
- [11] 11. Cascino G, Ceres R, Monteleone AM, Bucci P, Giordano GM, Galderisi S, Monteleone P. Switching Antipsychotic Medications in People with



- Schizophrenia: A 4-Year Naturalistic Study. *Journal of Clinical Medicine*. 2022 Oct 10;11(19):5965.
- [12] 12. Markiewicz-Gospodarek A, Markiewicz R, Dobrowolska B, Rahnema M, Łoza B. Relationship of neuropeptide S (NPS) with neurocognitive, clinical, and electrophysiological parameters of patients during structured rehabilitation therapy for schizophrenia. *Journal of Clinical Medicine*. 2022 Sep 6;11(18):5266.
- [13] 13. Barch DM, Karcher N, Moran E. Reinventing schizophrenia—Embracing complexity and complication. *Schizophrenia research*. 2022 Apr 1;242:7-11.
- [14] 14. Giordano GM, Giuliani L, Perrottelli A, Bucci P, Di Lorenzo G, Siracusano A, Brando F, Pezzella P, Fabrazzo M, Altamura M, Bellomo A. Mismatch negativity and P3a impairment through different phases of schizophrenia and their association with real-life functioning. *Journal of Clinical Medicine*. 2021 Dec 13;10(24):5838.
- [15] 15. Giordano GM, Pezzella P, Quarantelli M, Bucci P, Prinster A, Soricelli A, Perrottelli A, Giuliani L, Fabrazzo M, Galderisi S. Investigating the relationship between white matter connectivity and motivational circuits in subjects with deficit schizophrenia: a diffusion tensor imaging (DTI) study. *Journal of Clinical Medicine*. 2021 Dec 23;11(1):61.
- [16] 16. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatric disease and treatment*. 2020 Feb 21;519-34.
- [17] 17. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. *Schizophrenia bulletin*. 2006 Apr 1;32(2):238-45.
- [18] 18. Fabrazzo M, Cipolla S, Camerlengo A, Perris F, Catapano F. Second-generation antipsychotics' effectiveness and tolerability: a review of real-world studies in patients with schizophrenia and related disorders. *Journal of Clinical Medicine*. 2022 Aug 3;11(15):4530.
- [19] 19. Moritz S, Silverstein SM, Dietrichkeit M, Gallinat J. Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought. *World Psychiatry*. 2020 Jun;19(2):254.
- [20] 20. Talreja BT, Shah S, Kataria L. Cognitive function in schizophrenia and its association with socio-demographics factors. *Industrial psychiatry journal*. 2013 Jan;22(1):47.
- [21] 21. Srinivasan L, Thara R, Tirupati SN. Cognitive dysfunction and associated factors in patients with chronic schizophrenia. *Indian Journal of Psychiatry*. 2005 Jul;47(3):139.
- [22] 22. Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. *World psychiatry*. 2019 Jun;18(2):146-61.
- [23] 23. McCleery A, Horan WP, Green MF. Social cognition during the early phase of schizophrenia. In *Social cognition and metacognition in schizophrenia 2014* Jan 1 (pp. 49-67). Academic Press.
- [24] 24. Kaneko Y, Keshavan M. Cognitive remediation in schizophrenia. *Clinical Psychopharmacology and Neuroscience*. 2012 Dec;10(3):125.
- [25] 25. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICES conference to select cognitive domains and test criteria. *Biological psychiatry*. 2004 Sep 1;56(5):301-7.
- [26] 26. Lai CY, Scarr E, Udawela M, Everall I, Chen WJ, Dean B. Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. *World journal of psychiatry*. 2016 Mar 3;6(1):102.
- [27] 27. Hayashi-Takagi A, Vawter MP, Iwamoto K. Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research. *Biological psychiatry*. 2014 Jun 15;75(12):920-8.
- [28] 28. Bisso E, Signorelli MS, Milazzo M, Maglia M, Polosa R, Aguglia E, Caponnetto P. Immersive virtual reality applications in schizophrenia spectrum therapy: a systematic review. *International journal of environmental research and public health*. 2020 Sep;17(17):6111.
- [29] 29. Trémeau F. A review of emotion deficits in schizophrenia. *Dialogues in clinical neuroscience*. 2006 Mar 31;8(1):59-70.
- [30] 30. Willner K, Vasani S, Abdijadid S. Atypical antipsychotic agents.
- [31] 31. Jennings AA, Guerin N, Foley T. Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia



- in general practice: a modified eDelphi consensus study. *Clinical interventions in aging*. 2018 Oct 23;2107-17.
- [32] 32. Aida J, Chau B, Dunn J. Immersive virtual reality in traumatic brain injury rehabilitation: a literature review. *NeuroRehabilitation*. 2018 Jan 1;42(4):441-8.
- [33] 33. Bouchard S, Dumoulin S, Robillard G, Guitard T, Klinger E, Forget H, Loranger C, Roucaut FX. Virtual reality compared with in vivo exposure in the treatment of social anxiety disorder: a three-arm randomised controlled trial. *The British Journal of Psychiatry*. 2017 Apr;210(4):276-83.
- [34] 34. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia bulletin*. 1987 Jan 1;13(2):261-76.
- [35] 35. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect states. *Schizophrenia Bulletin*. 1985 Jan 1;11(3):409-19.
- [36] 36. Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. *Schizophrenia bulletin*. 2011 Mar 1;37(2):291-9.
- [37] 37. Mueser KT, Bellack AS, Morrison RL, Wixted JT. Social competence in schizophrenia: Premorbid adjustment, social skill, and domains of functioning. *Journal of psychiatric research*. 1990 Jan 1;24(1):51-63.
- [38] 38. Valiente-Gómez A, Mezquida G, Romaguera A, Vilardebò I, Andrés H, Granados B, Larrubia J, Pomarol-Clotet E, McKenna PJ, Sarró S, Bernardo M. Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS). *Schizophrenia research*. 2015 Aug 1;166(1-3):104-9.
- [39] 39. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. *Schizophrenia bulletin*. 2010 Mar 1;36(2):359-69.
- [40] 40. Amoretti S, Mezquida G, Rosa AR, Bioque M, Cuesta MJ, Pina-Camacho L, Garcia-Rizo C, Barcones F, Gonzalez-Pinto A, Merchan-Naranjo J, Corripio I. The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. *European Neuropsychopharmacology*. 2021 Jun 1;47:98-111.
- [41] 41. Bergh S, Hjorthøj C, Sørensen HJ, Fagerlund B, Austin S, Secher RG, Jepsen JR, Nordentoft M. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. *Schizophrenia research*. 2016 Aug 1;175(1-3):57-63.
- [42] 42. González-Ortega I, Rosa A, Alberich S, Barbeito S, Vega P, Echeburúa E, Vieta E, González-Pinto A. Validation and use of the functioning assessment short test in first psychotic episodes. *The Journal of nervous and mental disease*. 2010 Nov 1;198(11):836-40.]
- [43] 43. Brill N, Levine SZ, Reichenberg A, Lubin G, Weiser M, Rabinowitz J. Pathways to functional outcomes in schizophrenia: the role of premorbid functioning, negative symptoms and intelligence. *Schizophrenia research*. 2009 May 1;110(1-3):40-6.
- [44] 44. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. *Schizophrenia bulletin*. 1984 Jan 1;10(3):388-98.
- [45] 46. Malm U, May PR, Dencker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. *Schizophrenia Bulletin*. 1981;7(3):477.
- [46] 47. Karow A, Wittmann L, Schoettle D, Schaefer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. *Dialogues in clinical neuroscience*. 2014 Jun 30;16(2):185-95.
- [47] 48. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Archives of general psychiatry*. 2006 Oct 1;63(10):1079-87.
- [48] 49. Rodríguez A, Miarons R, Soler RM, Esparcia AJ, Rodríguez A. Estudio factorial y adaptación de la Escala de Calidad de Vida en la Esquizofrenia (QLS). *Revista de psicología general y aplicada: Revista de la Federación Española de Asociaciones de Psicología*. 1995;48(3):353-64.
- [49] 50. Karow A, Wittmann L, Schoettle D, Schaefer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. *Dialogues in clinical neuroscience*. 2014 Jun 30;16(2):185-95.